Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Rifaximin 550 Mg In Subjects With Severe Hepatic Impairment And Overt Hepatic Encephalopathy
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 11 Jan 2024
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary)
- Indications Hepatic encephalopathy
- Focus Therapeutic Use
- Sponsors Bausch Health Companies; Salix Pharmaceuticals
- 01 Nov 2023 Status changed from recruiting to discontinued.
- 07 Sep 2022 Planned End Date changed from 1 Jun 2023 to 1 May 2025.
- 07 Sep 2022 Planned primary completion date changed from 1 Jun 2023 to 1 May 2025.